Combination of Proton Irradiation and Targeted Radionuclide Therapy with 177Lu-PSMA-617 in a Tumor Mouse Model of Prostate Cancer

被引：0
|
作者：
Mueller, C. [1 ]
Perrin, R. [1 ]
Umbricht, C. [1 ]
van der Meulen, N. [1 ]
Safai, S. [1 ]
Weber, D. [1 ]
Lomax, A. [1 ]
Schibli, R. [1 ]
机构：
[1] Paul Scherrer Inst, Villigen, Switzerland
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2017年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-160
引用
收藏
页码：S180 / S181
页数：2
相关论文
共 50 条
  • [1] 177Lu-PSMA-617 for metastatic prostate cancer in India
    Ghose, Aruni
    Banerjee, Soirindhri
    Choudhury, Partha S.
    Maniam, Akash
    Gupta, Manoj
    Banna, Giuseppe L.
    Vasdev, Nikhil
    Ghose, Amit
    Noronha, Vanita
    Mitra, Swarupa
    LANCET REGIONAL HEALTH - SOUTHEAST ASIA, 2024, 30
  • [2] Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer
    Fendler, Wolfgang P.
    Stuparu, Andreea D.
    Evans-Axelsson, Susan
    Luckerath, Katharina
    Wei, Liu
    Kim, Woosuk
    Poddar, Soumya
    Said, Jonathan
    Radu, Caius G.
    Eiber, Matthias
    Czernin, Johannes
    Slavik, Roger
    Herrmann, Ken
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (11) : 1786 - 1792
  • [3] First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands
    van Kalmthout, Ludwike
    Braat, Arthur
    Lam, Marnix
    van Leeuwaarde, Rachel
    Krijger, Gerard
    Ververs, Tessa
    Mehra, Niven
    Bins, Adriaan
    Hunting, Jarmo
    de Keizer, Bart
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (06) : 446 - 451
  • [4] Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA617 in combination with ipilimumab and nivolumab for men with metastatic castrationresistant prostate cancer (mCRPC; ANZUP 2001).
    Sandhu, Shahneen
    Subramaniam, Shalini
    Hofman, Michael S.
    Stockler, Martin R.
    Martin, Andrew James
    Pokorski, Izabella
    Goh, Jeffrey C.
    Pattison, David A.
    Dhiantravan, Nattakorn
    Gedye, Craig
    Rutherford, Natalie K.
    Joshua, Anthony M.
    Tan, Thean Hsiang
    Kirkwood, Ian D.
    Weickhardt, Andrew James
    Lee, Sze Ting
    Alipour, Ramin
    Nguyen, Andrew
    Davis, Ian D.
    Emmett, Louise
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [5] Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy
    Filss, Christian
    Heinzel, Alexander
    Mueller, Berthold
    Vogg, Andreas T. J.
    Langen, Karl-Josef
    Mottaghy, Felix M.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2018, 57 (01): : 19 - 25
  • [6] A Hangover Under 177Lu-PSMA-617 Therapy
    Poterszman, Nathan
    Somme, Laura
    Bund, Caroline
    Hutt, Emilie
    Somme, Francois
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (06) : 582 - 583
  • [7] Radiation Dosimetry in 177Lu-PSMA-617 Therapy
    Jackson, Price
    Hofman, Michael
    McIntosh, Lachlan
    Buteau, James Patrick
    Kumar, Aravind Ravi
    SEMINARS IN NUCLEAR MEDICINE, 2022, 52 (02) : 243 - 254
  • [8] 177Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer
    Qu, Gengcuo
    Hua, Qingchu
    Li, Hongmei
    Zhang, Yu
    Chen, Yue
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (02) : 152 - 153
  • [9] 177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
    von Eyben, Finn E.
    Kiljunen, Timo
    Joensuu, Timo
    Kairemo, Kalevi
    Uprimny, Christian
    Virgolini, Irene
    ONCOTARGET, 2017, 8 (39) : 66112 - 66116
  • [10] Whole-Body Dosimetry in Therapy of Metastatic Prostate Cancer with 177Lu-PSMA-617
    Happel, C.
    Voeller, L.
    Kranert, W. T.
    Groener, D.
    Bockisch, B.
    Mader, N.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S695 - S695
12345